American College of Gastroenterology Updated HE Guidelines
New standards emphasize early rifaximin use and social infrastructure to manage hepatic encephalopathy.
Updated on Oct. 10, 2026 in Alzheimer’s
Live Poll
Do you trust that new medical guidelines prioritize the needs of patients and their caregivers?
The American College of Gastroenterology has issued updated clinical guidelines for managing hepatic encephalopathy. The new protocols prioritize social infrastructure and earlier intervention with rifaximin alongside lactulose to improve patient outcomes.
Why it matters
These guidelines aim to standardize clinical approaches to hepatic encephalopathy, focusing on recurrence prevention to reduce hospital readmissions. By incorporating social infrastructure as a core axis of care, the board seeks to address non-clinical triggers that impact long-term recovery.
Approximately 80% of patients are expected to improve following a lactulose trial, while 10% to 15% are anticipated to fail the treatment. Clinicians are advised to reassess patients 8 weeks after starting therapy.
The players
American College of Gastroenterology
This is a professional medical association that promotes the highest standards of gastroenterological care through education and research.
The details
The guidance clarifies that blood ammonia levels should not be used as a standalone diagnostic tool, favoring patient and caregiver reports for clinical assessment. Acute kidney injury and infection are identified as increasingly common triggers that outpace gastrointestinal bleeding for hospital admissions.
Timeline
October 9, 2026: The American College of Gastroenterology published the guideline summary.
8 weeks: The designated timeframe for patient reassessment following the initiation of lactulose.
Deeper Dive
The guidelines utilize the Bristol stool scale to provide a standardized measurement tool for titration of lactulose dosing. This approach follows the established clinical practice of using validated diagnostic references to manage complex gastrointestinal symptoms.
Patients may experience shifts in their treatment plans as doctors prioritize earlier rifaximin use and focus on social support systems. Clinicians are encouraged to spend additional time during appointments educating caregivers, which may lead to more comprehensive support during the recovery process.
The takeaway
Clinicians and caregivers should prioritize consistent symptom monitoring and clear communication to prevent hospital readmissions. Removing the diagnosis is recommended if a patient fails a theragnostic trial, acknowledging the potential for misdiagnosis.
Further reading
For more information on the management of neurocognitive decline, visit our Alzheimer’s section.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you trust that new medical guidelines prioritize the needs of patients and their caregivers?
